X

Vous n'êtes pas connecté

Rubriques :

Maroc Maroc - ONCOLOGYNEWS.COM.AU - A La Une - 06/Feb 09:46

Phase III PATINA study results published

Alliance Foundation Trials, LLC (AFT) today announced the publication of the pivotal phase III PATINA study (AFT-38) in the New England Journal of Medicine (NEJM), marking a major milestone for patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–positive (HER2+) advanced breast cancer (ABC). The study’s results demonstrate that the addition of the CDK4/6 inhibitor [...]

Articles similaires

Sorry! Image not available at this time

Phase III PATINA study results published

oncologynews.com.au - 06/Feb 09:46

Alliance Foundation Trials, LLC (AFT) today announced the publication of the pivotal phase III PATINA study (AFT-38) in the New England Journal of...

Sorry! Image not available at this time

Addition of Palbociclib Improves PFS in HR-Positive, HER2-Positive Metastatic Breast Cancer

drugs.com - 02/Feb 15:02

MONDAY, Feb. 2, 2026 -- For patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive metastatic breast...

Sorry! Image not available at this time

ASCENT-04/KEYNOTE-D19: Sacituzumab govitecan plus pembrolizumab in metastatic triple-negative breast cancer

oncologynews.com.au - 27/Jan 15:30

Metastatic triple-negative breast cancer (TNBC) remains one of the most difficult breast cancer subtypes to treat, with limited durable responses to...

Sorry! Image not available at this time

ASCENT-04/KEYNOTE-D19: Sacituzumab govitecan plus pembrolizumab in metastatic triple-negative breast cancer

oncologynews.com.au - 27/Jan 15:30

Metastatic triple-negative breast cancer (TNBC) remains one of the most difficult breast cancer subtypes to treat, with limited durable responses to...

Sorry! Image not available at this time

Genentech’s Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS)

wn.com - 07/Feb 23:52

– Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority...

Sorry! Image not available at this time

Epithelial–mesenchymal transition (EMT) and its role in acquired epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) chemoresistance in non-small cell lung cancer (NSCLC)

oncologynews.com.au - 30/Jan 13:40

Epithelial–mesenchymal transition (EMT) is a biological process that involves the transformation of epithelial cells into cells with a mesenchymal...

Sorry! Image not available at this time

Sanofi’s Venglustat Met All Primary Endpoints in a Phase 3 Study of Type 3 Gaucher Disease

drugs.com - 02/Feb 00:02

Paris, February 2, 2026. Positive results from the LEAP2MONO phase 3 study (clinical study identifier: NCT05222906) demonstrated that venglustat met...

Sorry! Image not available at this time

Genentech Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People Living With Obesity

drugs.com - 26/Jan 18:01

South San Francisco, CA -- January 26, 2026 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline...

Sorry! Image not available at this time

Genentech Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People Living With Obesity

drugs.com - 26/Jan 18:01

South San Francisco, CA -- January 26, 2026 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline...

Sorry! Image not available at this time

Oral cancer pain and opioid tolerance share a common EGFR mechanism

news.medical.net - 30/Jan 03:38

Epidermal growth factor receptor (EGFR) signaling in the tissue around oral cancers both increases nerve sensitivity and makes opioids less effective,...

Les derniers communiqués